While pharmaceutical stocks had their worst time in the third quarter, they also struggled with the market capitalization rankings.
Newsmp collected data of Q3 market cap rankings of 59 pharmaceutical-related stocks (including preferred stocks) out of 938 listed stocks in the securities market (as of Sept 30) and found that only 8 stocks rose during the period.
On the other hand, the market capitalization rankings of 50 stocks at the end of September were lower than that of June.
In the securities market, the number of pharmaceutical stocks, which ranked in the top 100 by market capitalization, decreased from 8 stocks at the end of June to 6 at the end of September.
While pharmaceutical stocks were struggling, PharmGen Science moved up 42 spots in the ranking, and Daewon Pharmaceutical also climbed 39 spots.
Dong Wha Pharm then jumped 15 spots, Reyon Pharmaceutical 14 spots, SK Bioscience 9 spots, Samsung Biologics and Hana Pharm 3 spots, and Dongsung Pharmaceutical 2 spots.
However, during the same period, Shing Poong Pharmaceutical Co. Ltd. Pfd. Series 1 plunged 129 spots, Jeil Pharma Holdings 83 spots, CKD Bio 74 spots, Kyongbo Pharmaceutical 66 spots, JW Holdings 54 spots, Samsung Pharmaceutical 51 spots, and JW Lifescience and Whanin Pharmaceutical 50 spots, 8 stocks down more than 50 spots.
Amidst the struggles of pharmaceutical stocks, the top three bio leaders showed strength. Samsung Biologics moved up 3 spots from No. 7 to No. 4, Celltrion maintained its No. 10 position, and SK Bioscience advanced from No. 32 to No. 23.
In the meantime, Yuhan Corporation dropped from No. 74 to No. 78, Hanmi Science from No. 66 to No. 80, and Green Cross Corporation from No. 89 to No. 90.
Hanmi Pharmaceutical moved back from No. 82 to No. 104, and Shin Poong Pharmaceutical slid from No. 72 to No. 111, falling out of the top 100.
Daewoong, Daewoong Pharmaceutical, and Gene One Life Science, which were ranked between No. 100 and No. 150, were all pushed out of the top 150, and Green Cross Holdings, Chong Kun Dang Pharmaceutical, Boryung Pharmaceutical, HanAll Biopharma, and Bukwang Pharmaceutical also fell, while the three companies, Boryung Pharmaceutical, HanAll Biopharma, and Bukwang Pharmaceutical, fell out of the top 200.
Although Reyon Pharmaceutical raised its ranking from No. 244 to No. 230, Yungjin Pharm., Pharmicell, Korea United Pharm., Dong-A Socio Holdings, Dong-A ST, Il-Yang Pharmaceutical, JW Pharmaceutical, and Jeil Pharmaceutical, which are located between No. 200 and No. 300, all fell.
Among them, JW Pharmaceutical and Jeil Pharmaceutical were pushed out of the top 300, and only four of the top 25 pharmaceutical-relate stocks in the top 300, including the three bio leaders and Reyon Pharmaceutical, were exempted from depreciation.